Glimmers of Hope for Targeting p53
Unknown authors
Abstract
In two ongoing phase I trials, PC14586, a Y220C-selective structural corrector of mutant p53, and BI 907828, an MDM2-p53 antagonist, appear safe and tolerable, showing signs of efficacy. These emerging data offer hope that a key tumor suppressor may not be as undruggable as previously thought.
Topics & Concepts
SuppressorMdm2Key (lock)Computational biologyMutantAntagonistBiologyBioinformaticsCancer researchCancerGeneticsReceptorApoptosisGeneEcologyCancer-related Molecular PathwaysPARP inhibition in cancer therapyEpigenetics and DNA Methylation